IDL Diagnostics AB (publ.) publishes the nomination committee’s composition for the AGM in 2026.

The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on May 15th, 2025, consists of:

• Jerker Swanstein, (chairman of the nomination committee), representing Labbex Förvaltnings AB
• Jon Eiken, representing own shares
• Didrik Hamilton, representing own shares

Before the annual general meeting 2026, the nomination committee shall prepare a proposal for the election of the chairman and other members of the board of directors, the election of the chairman of the annual meeting, the election of auditors, the determination of fees, and matters pertaining to it.

For more information, please visit:
Nomination committee - IDL Diagnostics

Shareholders who wish to submit proposals to the nomination committee for the annual general meeting 2026 can e-mail info@idldiagnostics.com  (header ” IDL Diagnostics’ nomination committee”) or via letter to:

IDL Diagnostics AB
Att: Valberedning
P.O Box 11151
SE-161 11 Bromma
Sweden

The proposals should be submitted to the nomination committee before January 31st, 2026.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com

About IDL Diagnostics

IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.idldiagnostics.com

Attachments

IDL Diagnostics nomination committee for the AGM 2026

Läs mer på MFN